A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation – a socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 131 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 70 countries worldwide.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
John Edward Butler Ransohoff

John Edward Butler Ransohoff

Vice President, Head of Strategic Projects for Innovations and International Partnerships Direction, Bayer AG
Biography
John leads Bayer global external innovation partnerships, including development of alliances with well-established international scientists and research organizations, as well as young and promising scientific start-ups.

John joined Bayer January 1988 as a Laboratory Head in Medicinal Chemistry.

Between 1992 and 1999 he was a Project Manager in Drug Development.

1999 he was named Corporate Vice-president in charge of the Central Coordination of R&D. He spend 6 years in Strategic Planning both at Corporate and Pharmaceutical Division levels, during that period he lead strategy projects in areas such as Therapeutic Proteins, Hematology Research, Innovation in Glucose Monitoring, Toxicology Operations, for several divisions of Bayer AG.

In 2007 he joined Bayer Innovations as Global Project Leader Plant-made-Pharmaceuticals. In this function he was responsible for the development of a technology platform to express therapeutic proteins in planta, in particular, he lead the development of Bayer’s autologous therapeutic cancer vaccine against Non-Hodgkin’s Lymphoma. This included the oversight of investment in a manufacturing plant, introduction of GMPs, certification by local authorities and finally, conducting a proof-of-concept study in patients.

Since 2014, John has been with the Global External Innovations Group, in charge of Venture Capital Investment and European Projects with impact in clinical development.

A native of the Dominican Republic, John studied Chemistry at Heidelberg University. He worked as a research fellow at the Max-Planck-Institute for Medical Research (Heidelberg) and obtained a Dr.rer.nat. in 1986. He spent two years as Research Associate at Rockefeller University (Tom Kaiser’s Lab) conducting work in molecular biology and enzymology of phosphatases.

John is a member of the Scientific Advisory Board of the Institute for Infection and Immunity at St George's, University of London. He is a former member of the German Research Council Evaluation Committee of Chemistry Faculties.